comparemela.com
Home
Live Updates
Dizal Announces New Data from the Phase I/II Study of Golido
Dizal Announces New Data from the Phase I/II Study of Golido
Dizal Announces New Data from the Phase I/II Study of Golidocitnib in Refractory or Relapsed Peripheral T Cell Lymphoma Selected for Oral Presentation at 2022 EHA Annual Meeting
/PRNewswire/ -- Dizal (SSE: 688192) will present the data from an ongoing phase I/II study of golidocitnib, a selective JAK1 inhibitor, in refractory or...
Related Keywords
Austria ,
Shanghai ,
China ,
Vienna ,
Wien ,
Seog Kim ,
Xiaolin Zhang ,
International Conference On Malignant Lymphoma ,
Samsung Medical Center ,
European Hematology Association ,
Business Development ,
Hybrid Congress ,
Track Designation ,
Malignant Lymphoma ,
Chief Executive Officer ,
Fast Track ,
Aggressive Lymphoma ,
Abstract Code ,
Won Seog Kim ,
Samsung Medical ,
Dizal Pharmaceutical ,